Zepbound KwikPen approved and launched in Canada for chronic weight management

Eli Lilly Canada said on July 9, 2025 that Zepbound KwikPen (tirzepatide injection) is now available in Canada for chronic weight management in adults. Health Canada authorized the product on May 13, 2025, according to the company, and Lilly describes it as the first and only Health Canada-approved obesity treatment that activates both the GIP and GLP-1 hormone receptors ^[1].

The KwikPen is a once-weekly injection used alongside a reduced-calorie diet and increased physical activity ^[1]. It is authorized for adults with obesity, defined as a body mass index of 30 kg/m2 or higher, and for adults who are overweight, with a BMI of 27 kg/m2 to under 30 kg/m2, who also have at least one weight-related medical condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease ^[1].

The trial numbers behind the approval

Health Canada's authorization was based on results from the phase 3 SURMOUNT-1, SURMOUNT-2, SURMOUNT-3 and SURMOUNT-4 trials, the company said ^[1]. In SURMOUNT-1, which enrolled 2,539 adults with obesity, or with excess weight and weight-related medical conditions but not diabetes, people taking tirzepatide plus diet and exercise lost significantly more weight than those on placebo at 72 weeks. At the highest dose of 15 mg, average weight loss was 21.8 kg (48 lbs). At the lowest dose of 5 mg, average loss was 15.4 kg (34 lbs). The placebo group lost an average of 3.2 kg (7 lbs) ^[1].

Lilly said the SURMOUNT program began in late 2019 and has enrolled more than 5,000 people with obesity or overweight across six registration studies, four of them global ^[1].

Obesity in Canada, in the company's framing

Lilly cites figures showing one in three Canadians live with obesity, and puts the economic cost of not treating obesity in Canada at $27.6 billion ^[1]. The company also cites survey data indicating that 54% of adults with obesity report being stigmatized by coworkers, and that nearly two-thirds, 64%, have experienced weight bias from a health care professional ^[1].

"This will increase the options for weight management. This is a win for Canadians who struggle with obesity and obesity related conditions," said Dr. Sean Wharton, an internal medicine physician and weight management specialist, in the announcement ^[1]. Dr. Yves Robitaille, an obesity management specialist, called the approval "a significant advancement" ^[1].

Lisa Schaffer, executive director of Obesity Canada, said the country is "entering a new era in obesity care" but added that new tools need to be "truly accessible," not just available ^[1]. Priti Chawla, executive director of Obesity Matters/Parlons Obésité, said access to effective care "must be guided by need—not privilege," and called on governments and employers to ensure equitable access ^[1].

Why it matters for patients

Tirzepatide is the active ingredient in Zepbound, used for chronic weight management in the US, and in Mounjaro, used for type 2 diabetes. The news out of Canada concerns a delivery format rather than a new molecule: a multi-dose pen that gives more than one weekly dose per device, which can change how many injection devices a patient handles per month. Whether that pen format will be authorized or sold in the US has not been disclosed.

Access is the open question in Canada too. The announcement does not say what the KwikPen will cost, whether provincial drug plans or private insurers will cover it, or what criteria they would apply. Obesity Matters is publicly pressing governments and employers on that point ^[1]. For patients tracking GLP-1 and dual-agonist options, the practical difference between a drug being approved and a drug being paid for remains the part that is usually announced last.

The eligibility rules also matter. Canada's authorization ties coverage of the indication to BMI thresholds plus at least one weight-related condition for the lower BMI group ^[1], the same structure used in other markets for this class. Adults who fall below those thresholds would not be covered by the approved indication.

What happens next

Lilly has not disclosed pricing, reimbursement timelines or which Canadian jurisdictions will list the product, and no coverage decision dates have been reported ^[1]. Health Canada authorized the product on May 13, 2025, roughly eight weeks before the July 9 availability announcement ^[1].